Hostname: page-component-cb9f654ff-c75p9 Total loading time: 0 Render date: 2025-08-06T17:02:34.818Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Treatment on Contagiousness of Patients With Active Pulmonary Tuberculosis

Published online by Cambridge University Press:  02 January 2015

Dick Menzies
Dick Menzies*
Affiliation:
Montreal Chest Institute and Respiratory Epidemiology Unit, McGill University, Montreal, Quebec, Canada
*
Montreal Chest Institute, 3650 St Urbain, Montreal, Quebec 42X 2P4, Canada
Get access Rights & Permissions [Opens in a new window]

Abstract

In view of the important consequences with regard to policies for respiratory isolation of hospitalized patients with active tuberculosis, the duration of contagiousness after initiation of effective therapy was reviewed. All relevant English-language literature was reviewed to identify in vitro, animal experimental, and epidemiological evidence regarding contagiousness of patients with active tuberculosis after initiation of therapy.

Based on in vitro evidence of numbers of tubercle bacilli initially present and rapidity of reduction with therapy, it can be predicted that patients whose respiratory secretions are initially smear-negative but culture-positive should no longer have viable bacilli detectable by culture within 2 weeks. Based on the same evidence, it can be predicted that, after 2 weeks of therapy, almost all smear-positive patients will remain culture-positive, and more than one half will remain smear-positive. There are few epidemiological studies of this issue, most of which have had major methodological weaknesses. None of the results from these studies can be considered relevant to the hospital environment, where the majority of workers are uninfected and patients are potentially immunocompromised.

Animal and in vitro evidence suggest that patients with active tuberculosis remain contagious at least 2 weeks after the initiation of therapy. Patients with smear-positive disease are likely to be contagious much longer. There is no relevant and valid epidemiological evidence regarding this issue.

Information

Type
Readers' Forum
Information
Infection Control & Hospital Epidemiology , Volume 18 , Issue 8 , August 1997 , pp. 582 - 586
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Fischl, MA. Nosocomial transmission of multi-drug resistant tuberculosis among HIV-infected persons―Florida and New York, 1988-1991. MMWR 1991;40:585–591.Google Scholar
2. Coronado, V, Beck-Sague, C, Hutton, M, et al. Transmission of multi-drug resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment polymorphism analysis. J Infect Dis 1993;168:1052–1055.Google Scholar
3. Pearson, ML, Jereb, JA, Frieden, TR, Crawford, JT. Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis: a risk to patients and healthcare workers. Ann Intern Med 1992;117:191–196.Google Scholar
4. Beck-Sague, C, Dooley, SW, Hutton, MD, et al. Hospital outbreak of multi-drug resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA 1992;268:1280–1286.CrossRefGoogle Scholar
5. Edlin, BR, Tokars, JI, Grieco, MH, et al. An outbreak of multi-drug resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514–1521.Google Scholar
6. Centers for Disease Control. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990;39:1–29.Google Scholar
7. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992;146:1623–1633.CrossRefGoogle Scholar
8. Centers for Disease Control and Prevention. Draft guidelines for preventing the transmission of tuberculosis in health care facilities. 2nd ed. Federal Register 1993;58:52810–52854.Google Scholar
9. Centers for Disease Control and Prevention. Recommendations and reports. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR 1994;43:13.Google Scholar
10. Menzies, RI, Fanning, A, Yuan, L, Fitzgerald, JM. Tuberculosis among health care workers. N Engl J Med 1995;332:92–98.Google Scholar
11. Jarvis, WR, Bolyard, EA, Bozzi, CJ, et al. Respirators, recommendations, and regulations: the controversy surrounding protection of health care workers from tuberculosis. Ann Intern Med 1995;122:142–146.Google Scholar
12. Iseman, MD. A leap of faith: what can we do to curtail intrainstitutional transmission of tuberculosis? Ann Intern Med 1992;117:251–253.CrossRefGoogle ScholarPubMed
13. Leff, A, Geppert, EF. Public health and preventive aspects of pulmonary tuberculosis. Arch Intern Med 1979;139:1405–1410.Google Scholar
14. Rouillon, A, Perdrizet, S, Parrot, R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976;57:275–299.Google Scholar
15. American Thoracic Society. Bacteriologic standards for the discharge of patients. Am Rev Respir Dis 1974;102:470–473.Google Scholar
16. Menzies, RI. Tuberculosis control in hospitals. In: Fitzgerald, JM, ed. Canadian Tuberculosis Standards. Ottawa, Ontario, Canada: Canadian Lung Association; 1995.Google Scholar
17. Health Canada. Guidelines for preventing the transmission of tuberculosis in Canadian health care facilities and other institutional settings. Ottawa, Ontario, Canada: Government of Canada; 1996.Google Scholar
18. Wells, WF. Airborne Contagion and Air Hygiene: An Ecological Study of Droplet Infections. Cambridge, MA: Harvard University Press; 1955.Google Scholar
19. Rose, CE, Zerbe, GO, Lantz, SO, Bailey, WC. Establishing priority during investigation of tuberculosis contacts. Am Rev Respir Dis 1979;119:603–609.Google Scholar
20. Riley, RL, Nardell, EA. Clearing the air: the theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989;139:1286–1294.Google Scholar
21. Riley, RL. Airborne infection: strategies for interrupting transmission. Bull Int Union Tuberc Lung Dis 1991;66:55–56.Google Scholar
22. Toman, K. Tuberculosis—Case-Finding and Chemotherapy: Questions and Answers. Geneva, Switzerland: World Health Organization; 1979.Google Scholar
23. Loudon, RG, Spohn, SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969;99:109–111.Google Scholar
24. Hertzberg, G. The infectiousness of human tuberculosis. Acta Tuberc Scand 1957;38(suppl):1–146.Google ScholarPubMed
25. Van Geuns, HA, Meijer, J, Styblo, K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975;50:107–121.Google ScholarPubMed
26. Grzybowski, S, Barnett, GD, Styblo, K. Contacts of cases of active pulmonary tuberculosis. Bull IUAT 1975;50:90–106.Google Scholar
27. Capewell, S, Leitch, AG. The value of contact procedures for tuberculosis in Edinburgh. Br J Dis Chest 1984;78:317–328.Google Scholar
28. Riley, RL, Mills, CC, O'Grady, FO, Sultan, LU, Wittstadt, F, Shivpuri, DN. Infectiousness of air from a tuberculosis ward: ultraviolet irradiation of infected air—comparative infectious-ness of different patients. Am Rev Respir Dis 1962;85:511–525.Google ScholarPubMed
29. Jindani, A, Aber, VR, Edwards, EA, Mitchison, DA. The early bacterial activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939–949.Google Scholar
30. Singapore Tuberculosis Service, British Medical Research Council. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore. Lancet 1975;7945:1105–1109.Google Scholar
31. East African, British Medical Research Council. Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972;7760:1079–1085.Google Scholar
32. Tousek, J, Votruba, R. Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. Chemotherapy 1974;20:183–200.Google Scholar
33. Tuberculosis Research Center. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 1983;64:73–91.Google Scholar
34. Kim, TC, Blackman, RS, Heatwole, KM, Kim, T, Rochester, DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Am Rev Respir Dis 1984;129:264–268.Google Scholar
35. Clancy, LJ, Kelly, P, O'Reilly, L, Byrne, C, Costello, E. The patho-genicity of Mycobacterium tuberculosis during chemotherapy. Eur Respir J 1990;3:399–402.Google Scholar
36. Loudon, RG, Bumgarner, LR, Coffman, GK. Isoniazid and the survival of tubercule bacilli in airborne droplet nuclei. Am Rev Respir Dis 1969;100:172–176.Google Scholar
37. Haley, CE, McDonald, RC, Rossi, L, Jones, WD, Haley, RW, Luby, JP. Tuberculosis epidemic among hospital personnel. Infect Control Hosp Epidemiol 1989;10:204–210.Google Scholar
38. Kamat, SR, Dawson, JJY, Devadatta, S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ 1966;34:517–532.Google Scholar
39. Gunnels, JJ, Bates, JH, Swindoll, H. Infectivity of sputum-positive patients on chemotherapy. Am Rev Respir Dis 1974;109:323–330.Google Scholar
40. Riley, RL, Moodie, AS. Infectivity of patients with pulmonary tuberculosis in inner-city homes. Am Rev Respir Dis 1974;110:810–812.Google Scholar
41. Brooks, SM, Lassiter, NL, Young, EC. A pilot study concerning the infection risk of sputum positive tuberculous patients on chemotherapy. Am Rev Respir Dis 1973;108:799–803.Google Scholar
42. Abeles, H. Early hospital discharge of tuberculous patients with sputum containing acid-fast bacilli on microscopic examination. Am Rev Respir Dis 1973;108:975–977.Google Scholar
43. Snider, DE, Kelly, GD, Cauthen, GM, Thompson, NJ, Kilburn, JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125–132.Google Scholar
44. Aitken, ML, Anderson, KM, Albert, RK. Is the tuberculosis screening program of hospital employees still required? Am Rev Respir Dis 1987;136:805–807.Google Scholar
45. Vogeler, DM, Burke, JP. Tuberculosis screening for hospital employees: a five-year experience in a large community hospital. Am Rev Respir Dis 1978;117:227–232.Google Scholar
46. Raad, I, Cusick, J, Sherertz, RJ, Sabbagh, M, Howell, N. Annual tuberculin skin testing of employees at a university hospital: a cost-benefit analysis. Infect Control Hosp Epidemiol 1989;10:465–468.Google Scholar
47. Adal, KA, Anglim, AM, Palumbo, CL, Titus, MG, Coyner, BJ, Farr, BM. Preventing nosocomial tuberculosis with HEPA respirators: a cost-effectiveness analysis. N Engl J Med 1994;331:169–173.CrossRefGoogle ScholarPubMed
48. Menzies, RI, Vissandjee, B, Rocher, I, St. Germain, Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190–198.Google Scholar
49. Daley, CL, Small, PM, Schecter, GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. N Engl J Med 1992;326:231–235.Google Scholar
50. Fischl, MA, Daikos, GL, Uttamchandani, RB, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug resistant bacilli. Ann Intern Med 1992;117:184–190.CrossRefGoogle ScholarPubMed
51. Fischl, MA, Uttamchandani, RB, Daikos, GL, et al. An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177–183.Google Scholar
52. Alland, D, Kalkut, GE, Moss, AR, et al. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994;330:1710–1716.CrossRefGoogle ScholarPubMed
53. Small, PM, Hopewell, PC, Singh, SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703–1709.Google Scholar
54. Genewein, A, Telenti, A, Bernasconi, C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet 1993;342:841–844.Google Scholar